Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Clin Cancer Res. 2019 Sep 27;26(1):290–300. doi: 10.1158/1078-0432.CCR-19-1351

Figure 2. EZH2 inhibition enhances antigen presentation and Th1-type chemokine expression levels in human HNSCC lines.

Figure 2.

A. SCC9, SCC25, CAL27, and CAL33 were treated with increasing concentrations of GSK126 or EPZ6348 (1 nM-100 μM) for 72 hours to test assess impact on cell viability. B. Human HNSCC cells were treated with GSK126 (10 μM), EPZ6438 (10 μM), or DMSO as control for 72 hours. IFNγ was added in the last 24 hours of drug incubation for all assays shown. HLA cell surface protein levels were measured by flow cytometry. The data are representative of 2 independent experiments. C. B2M and CXCL10 mRNA expression levels were quantified by qRT-PCR. Relative mRNA levels were normalized to GAPDH. *P<0.05, **P<0.01, ***P<0.001. Significance was calculated by one-way ANOVA. Data are shown as Mean± SD.